Please assess the completion status of the following clinical trial:

Trial Title: Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of iron overload, defined as serum ferritin \> 1,000 ng/mL and liver iron concentration ≥ 5 mg iron/g on tissue proton transverse relaxation rates Magnetic Resonance Imaging (MRI)~* Underwent prior allogeneic hematopoietic stem cell transplantation (HSCT) using either myeloablative or reduced-intensity conditioning at least 12 months ago~* No evidence of relapse or progression of the primary disease for which allogeneic HSCT was performed~* Patients who have become red-cell transfusion independent (i.e., no red cell transfusions within the past 3 months) as well as patients who require red cell transfusions are eligible~* Meets one of the following criteria:~  * Ineligible for phlebotomy (hemoglobin \< 11 g/dL, poor intravenous access, or unable to undergo phlebotomy every 4 weeks)~ * Have failed treatment with phlebotomy (serum ferritin \> 50% of baseline after 3 months of phlebotomy)~ * Refused phlebotomy~* ECOG performance status of 0-2~* Life expectancy ≥ 6 months~* Adequate renal function defined as serum creatinine \< or = 1.6 mg/dL and creatinine clearance of \> or = 60 ml/min calculated using the Crockcroft-Gault formula on 2 occasions within 30 days of enrollment~* Sexually active men and women must use an effective method of contraception. Alternatively, women must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal.~* Must be able to give written informed consent.~* Prior therapy with deferoxamine allowed provided it was completed ≥ 12 months ago~Exclusion Criteria:~* Contraindication for performing MRI or inability to undergo MRI because of claustrophobia or weight (\>350 pounds).~* Inability to take medications orally.~* Uncontrolled bacterial, viral, or fungal infection~* ANC ≥ 1,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Platelet count ≥ 50,000/mm³~* Aspartate aminotransferance (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal~* Less than 4 weeks since prior and no concurrent systemic investigational drug~* Less than 7 days since prior and no concurrent topical investigational drug. Concurrent non-investigational medications needed to treat concomitant medical conditions are allowed, with the exception of other chelating agents. Concurrent growth factors such as epoetin alfa, darbepoetin alfa, filgrastim (G-CSF), and sargramostim (GM-CSF) allowed. Concurrent irradiated packed red-cell and platelet transfusions allowed as clinically indicated. Concurrent low-doses of vitamin C supplements (≤ 200 mg/day) allowed.~* Concurrent iron supplements or multivitamins with iron.~* Aluminum-containing antacid therapies may not be taken simultaneously with deferasirox, but may be taken 2 hours before or after administration of deferasirox~* On dialysis or status post-renal transplantation~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Deferasirox Treated (Type: EXPERIMENTAL): Includes patients that were treated with deferasirox for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues